|Median Technologies SA -- France Stock|| |
EUR 8.85 0.14 1.56%
Vice President - Business Development Pharma
Mr. Jerome Windsor has served as Vice President Business Development Pharma at Median Technologies SA. He was former Vice President of commercial development and Strategic Partners of i3, UnitedHealth group subsidiary dedicated to Clinical Research and has over 16 years experience in pharmaceutical, biotech and CRO industries. He previously was European Development Manager at Covance, Cerep, and Consultant at Pricewaterhousecoopers and Accenture
33 4 93 33 37 77 http://www.mediantechnologies.com
Windsor is cofounder of ANS Biotech, a research company specialized in pain pharmacology. He is Pharm.D. and holds a MBA from ESSEC French Business School.
The company has return on total asset (ROA)
of (25.03) %
which means that it has lost $25.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (52.51) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 122 K in total debt with debt to equity ratio (D/E) of 0.3 which may suggest the company is not taking enough advantage from borrowing. Median Technologies SA has Current Ratio of 5.53 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
MEDIAN Technologies S.A. offer medical imaging solutions and services for diagnosing and monitoring cancer patients in routine clinical practice and clinical drug development. Median Technologies SA (ALMDT) is traded on Paris Stock Exchange in France. It is located in Valbonne, and employs 87 people.